Journal of radiological science and technology (대한방사선기술학회지:방사선기술과학)

Korean Society of Radiological Science (대한방사선과학회)
권호 표지
DOI QR코드

DOI QR Code

Comprehensive Clinical Study of Concurrent Chemotherapy Breathing IMRT Middle Part of Locally Advanced Esophageal Cancer

국소진행성 중위부 식도암의 동시항암화학 호흡동조 세기변조방사선치료의 포괄적인 임상고찰

  • Jung, Jae Hong (Dept. of Radiation Oncology, College of Medicine, Soonchunhyang University of Korea) ;
  • Kim, Seung-Chul (Dept. of Radiology, Songho College of Korea) ;
  • Moon, Seong-Kwon (Dept. of Radiation Oncology, College of Medicine, Soonchunhyang University of Korea)
  • 정재홍 (순천향대학교 부천병원 방사선종양학과) ;
  • 김승철 (송호대학교 방사선과) ;
  • 문성권 (순천향대학교 부천병원 방사선종양학과)
  • Received : 2015.11.24
  • Accepted : 2015.12.07
  • Published : 2015.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

The standard treatment of locally advanced type of mid-esophageal cancer is concurrent chemoradiation therapy (CRT). We evaluated the feasibility of chemotherapy with adding docetaxel to the classical basic regimens of cisplatin plus 5-fluorouracil (5-FU) and radiotherapy up to 70.2 Gy using dose escalations for esophageal cancer. It was possible to escalate radiation treatment dose up to 70.2 Gy by the respiratory-gated intensity-modulated radiotherapy (gated-IMRT) based on the 4DCT-simulation, with improving target coverage and normal tissue (ex., lung, heart, and spinal cord) sparing. This study suggested that the definitive chemo-radiotherapy with docetaxel, cisplatin, and 5-fluorouracil (i.e., DCF-R) and gating IMRT is tolerable and active in patients with locally advanced mid-esophageal cancer (AEC).

본 논문은 상당히 진행된 중위 식도암의 동시항암화학 방사선치료에 대한 분석의 것이다. 사용한 항암제는 전통적으로 사용되어온 시스플라틴, 5-플루오로우라실에, 도쎄탁실을 추가 시행하였다. 과거 식도암의 방사선치료에서는 총 선량 50.4 Gy/28회를 처방하였다. 하지만 현대의 방사선치료기술의 비약적인 발전으로, 호흡동조치료와 세기변조방사선치료를 적용하여, 정상조직의 손상을 최대한 감소시키면서 총 선량을 50.4 Gy이상으로 증가시키는 것이 가능하다. 이에 우리는, 도쎄탁실, 시스플라틴, 5-플루오로우라실 이라는 새로운 3제 병합요법(DCF-R)에 추가하여, 4DCT 모의시뮬레이션을 기반으로 한 호흡동조 세기변조방사선치료(gated-IGRT) 총 선량 70.2 Gy/39회를 동시에 시도하였으며, 치료기간 동안, 그리고 치료 종료 후 임상적으로 환자에게 위중한 합병증 및 부작용 발생은 관찰되지 않았다. 또한 생존율 향상을 이루어 냈다. 이를 바탕으로, 식도암의 새로운 치료방법을 제안한다.

Keywords

References

  1. Ulmer W, Pyyry J, Kaissi W: 3D photon superposition/ convolution algorithm and its foundation on results of Monte Carlo calculations, Phys Med Biol, 50(8), 1767-1790, 2005 https://doi.org/10.1088/0031-9155/50/8/010
  2. Geh JI, Bond SJ, Bentzen SM, Glymme-Jones R: Systematic overview of preoperative (neoadjuvant) chemo-radiotherapy trials in oesophageal cancer: evidence of a radiation and chemotherapy dose response, Radiother Oncol, 78(3), 236-234, 2006 https://doi.org/10.1016/j.radonc.2006.01.009
  3. Webb S, Nahum AE: A model for calculating tumour control probability in radiotherapy including the effects of inhomogeneous distributions of dose and clonogenic cell density, Phys Med Biol, 38(6), 653-666, 1993 https://doi.org/10.1088/0031-9155/38/6/001
  4. Gagliardi G, Constine LS, Moiseenko V, et al: Radiation dose-volume effects in the heart, Int J Radiat Oncol Biol Phys, 76, S77-85, 2010 https://doi.org/10.1016/j.ijrobp.2009.04.093
  5. Lyman JT: Complication probability as assessed from dose-volume histograms, Radiat Res Suppl, 8, S13-19, 1985 https://doi.org/10.2307/3583506
  6. Kutcher GJ, Burman C: Calculation of complication probability factors for non-uniform normal tissue irradiation: the effective volume method, Int J Radiat Oncol Biol Phys, 16(6), 1623-1630, 1989 https://doi.org/10.1016/0360-3016(89)90972-3
  7. Keall PJ, Mageras GS, Balter JM et al.: The management of respiratory motion in radiation oncology report of AAPM Task Group 76, Med Phys, 33(10), 3874-3900, 2006 https://doi.org/10.1118/1.2349696
  8. Cohen RJ, Paskalev K, Litwin S, Price RA Jr, Feigenberg SJ, Konski AA: Esophageal motion during radiotherapy: quantification and margin implications, Dis Esophagus, 23(6), 473-479, 2010 https://doi.org/10.1111/j.1442-2050.2009.01037.x
  9. Gao XS, Qiaol X, Cao L et al.: Pathological analysis of clinical target volume margin for radiotherapy in patients with esophageal and gastroesophageal junction carcinoma, Int J Radiat Oncol Biol Phys, 67(2), 389-396, 2007 https://doi.org/10.1016/j.ijrobp.2006.09.015
  10. Welsh J, Palmer MB, Aiani JA et al.: Esophageal cancer dose escalation using a simultaneous integrated boost technique, Int J Radiat Oncol Biol Phys, 82(1), 468-474, 2012 https://doi.org/10.1016/j.ijrobp.2010.10.023
  11. International Commission on Radiation Units and Measurements. ICRU report 62. Prescribing, recording and reporting photon beam therapy. Supplement to ICRU report 50 1999 Bethesda, MD: ICRU
  12. Keal P, Vedam SV, George R et al.: The clinical implementation of respiratory-gated intensitymodulated radiotherapy, Med Dosim, 31(2), 152-162, 2006 https://doi.org/10.1016/j.meddos.2005.12.002
  13. Wallis JW, Lerner TR, Lerner CA: Three-dimensional display in nuclear medicine, Med Imag IEEE Trans, 8(2), 297-330, 1989 https://doi.org/10.1109/42.41482
  14. Wolf MC, Stahl M, Krause BJ et al.: Curative treatment of esophageal carcinoma: Current options and future developments, Radiat Oncol, 6(1), 55, 2011 https://doi.org/10.1186/1748-717X-6-55
  15. Teoh AY, Chiu PW, Yeung WK et al.: Long-term survival outcomes after definitive chemoradiation versus surgery in patients with resectable squamous carcinoma of the esophagus: Results from a randomized controlled trial, Ann Oncol, 24(1), 165-171, 2012 https://doi.org/10.1093/annonc/mds206
  16. Cunningham D, Starling N, Ashley S: Capecitabine and oxaliplatin for advanced esophagogastric cancer, N Engl J Med, 362(9), 858-859, 2010 https://doi.org/10.1056/NEJMc0911925
  17. Button MR, Morgan CA, Croydon ES, Roberts SA, Crosby TD: Study to determine adequate margins in radiotherapy planning for esophageal carcinoma by detailing patterns of recurrence after definitive chemo-radiotherapy, Int J Radiat Oncol Biol Phys, 73(3), 818-823, 2009 https://doi.org/10.1016/j.ijrobp.2008.04.062
  18. Zhang Z, Liao Z, Jin J et al.: Dose-response relationship in locoregional control for patients with stage II-III esophageal cancer treated with concurrent chemotherapy and radiotherapy, Int J Radiat Oncol Biol Phys, 61(3), 656-664, 2005 https://doi.org/10.1016/j.ijrobp.2004.06.022
  19. Geh JI, Bond SJ, Bentzen SM, Glynne-Jones R: Systematic overview of preoperative (neoadjuvant) chemo-radiotherapy trials in oesophageal cancer: Evidence of a radiation and chemotherapy dose response, Radiother Oncol, 78(3), 236-244, 2005 https://doi.org/10.1016/j.radonc.2006.01.009
  20. Minsky BD, Pajak TF, Ginsberg RJ et al.: INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: High-dose versus standard-dose radiation therapy, J Clin Oncol, 20(5), 1167-1174, 2002 https://doi.org/10.1200/JCO.20.5.1167
  21. Gwynne S, Falk S, Gollins S et al.: Oesophageal chemo-radiotherapy in the UK: current practice and future directions, Clin Oncol (R Coll Radiol), 25(6), 368-377, 2013 https://doi.org/10.1016/j.clon.2013.01.006
  22. Martel MK, Sahijdak WM, Ten Haken RK, Kessler ML, Turrisi AT: Fraction size and dose parameters related to the incidence of pericardial effusions, Int J Radiat Oncol Biol Phys, 40(1), 155-161, 1998 https://doi.org/10.1016/S0360-3016(97)00584-1
  23. Hatakenaka M, Yonezawa M, Honda H: Acute cardiac impairment associated with concurrent chemo- radiotherapy for esophageal cancer: Magnetic resonance evaluation, Int J Radiat Oncol Biol Phys, 83(1), e67-e73, 2012 https://doi.org/10.1016/j.ijrobp.2011.12.018
  24. Bedenne L, Michel P, Bouche O et al.: Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102, J Clin Oncol, 25(10), 1160-1168, 2007 https://doi.org/10.1200/JCO.2005.04.7118
  25. Ishida K, Ando N, Yamamoto S, Ide H, Shioda M: Phase II study of cisplatin and 5 fluorouracil with concurrent radiotherapy in advanced squamous cell carcinoma of the esophagus: A Japan Esophageal Oncology Group (JEOG)/Japan Clinical Oncology Group trial (JCOG9516), Jpn J Clin Oncol, 34(10), 615-619, 2004 https://doi.org/10.1093/jjco/hyh107
  26. Ilson DH, Ajani J, Bhalla K et al.: Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus, J Clin Oncol, 16(5), 1826-1834, 1998 https://doi.org/10.1200/JCO.1998.16.5.1826
  27. Dunne AL, Mothersill C, Robson T, Wilson GD, Hirst DG: Radiosensitization of colon cancer cell lines by docetaxel: Mechanisms of action, Oncol Res, 14(9), 447-454, 2004 https://doi.org/10.3727/0965040041791455
  28. Higuchi K, Koisumi W, Hayakawa K: A phase I trial of definitive chemo-radiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) for advanced esophageal carcinoma: Kitasato digestive disease & oncology group trial (KDOG 0501), Radiother Oncol, 87(3), 398-404, 2008 https://doi.org/10.1016/j.radonc.2008.03.006
  29. Donahue JM, Nichols FC, S chomas DA et al.: Complete pathologic response after neoadjuvant chemo-radiotherapy for esophageal cancer is associated with enhanced survival, Ann Thorac Surg, 87(2), 398-398, 2009
  30. Siegel R, Naishadham D, Jemal A: Cancer statistics 2012, Cancer J Clin, 62(1), 10-29, 2012 https://doi.org/10.3322/caac.20138
  31. Orringer MB, Marshall B, Iannettoni MD: Transhiatal esophagectomy: clinical experience and refinements, Ann Surg, 230(3), 392-400, 1999 https://doi.org/10.1097/00000658-199909000-00012
  32. Chang AC, Ji H, Birkmeyer NJ, Orringer MB, Birkmeyer JD: Outcomes after transhiatal and transthoracic esophagectomy for cancer, Ann Thorac Surg, 85(2), 424-429, 2008 https://doi.org/10.1016/j.athoracsur.2007.10.007
  33. Suzuki A, Xiao L, Hayashi Y et al.: Prognostic significance of baseline positron emission tomography and importance of clinical complete response in patients with esophageal or gastroesophageal junction cancer treated with definitive chemo-radiotherapy, Cancer, 117(21), 4823-4833, 2011 https://doi.org/10.1002/cncr.26122
  34. Gillies RS, Middleston MR, Han C et al.: Role of positron emission tomography-computed tomography in predicting survival after neoadjuvant chemotherapy and surgery for oesophageal adenocarcinoma, Br J Surg, 99(2), 239-245, 2012 https://doi.org/10.1002/bjs.7758
  35. Prins MJ, Ruurda JP, van Diest PJ, van Hillegersberg R, Ten Kate FJ: The significance of the HER-2 status in esophageal adenocarcinoma for survival: an immunohistochemical and an in situ hybridization study, Ann Oncol, 24(5), 1290-1297, 2013 https://doi.org/10.1093/annonc/mds640